{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:26Z","timestamp":1783075946150,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T00:00:00Z","timestamp":1205798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T00:00:00Z","timestamp":1205798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1038\/tpj.2008.6","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T11:12:03Z","timestamp":1205838723000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3\u2032-untranslated region"],"prefix":"10.1038","volume":"9","author":[{"given":"L","family":"Greenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rigbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Strous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Teltsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Kanyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Korner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Ben-Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Lerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,18]]},"reference":[{"issue":"Suppl 1","key":"BFtpj20086_CR1","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1017\/S0317167100003309","volume":"30","author":"PJ Blanchet","year":"2003","unstructured":"Blanchet PJ . Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003; 30 (Suppl 1): S101\u2013S107.","journal-title":"Can J Neurol Sci"},{"key":"BFtpj20086_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/026988110401800303","volume":"18","author":"GP Reynolds","year":"2004","unstructured":"Reynolds GP . Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18: 340\u2013345.","journal-title":"J Psychopharmacol"},{"key":"BFtpj20086_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4088\/JCP.v65n0809","volume":"65","author":"JP Lindenmayer","year":"2004","unstructured":"Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M . Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084\u20131089.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20086_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1192\/bjp.187.2.137","volume":"187","author":"S Park","year":"2005","unstructured":"Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB . Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry 2005; 187: 137\u2013142.","journal-title":"Br J Psychiatry"},{"issue":"Suppl 3","key":"BFtpj20086_CR5","first-page":"iii22","volume":"253","author":"G Hirose","year":"2006","unstructured":"Hirose G . Drug induced parkinsonism: a review. J Neurol 2006; 253 (Suppl 3): iii22\u2013iii24.","journal-title":"J Neurol"},{"key":"BFtpj20086_CR6","first-page":"20","volume":"44","author":"V Lerner","year":"2007","unstructured":"Lerner V, Libov I, Kapstan A, Miodownik C, Dwolatzky T, Levine J . The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci 2007; 44: 20\u201328.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"BFtpj20086_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.mp.4002009","volume":"12","author":"MJ Arranz","year":"2007","unstructured":"Arranz MJ, de Leon J . Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707\u2013747.Jun 5; e-pub ahead of print.","journal-title":"Mol Psychiatry"},{"key":"BFtpj20086_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/FPC.0b013e32800ffbb4","volume":"17","author":"L Greenbaum","year":"2007","unstructured":"Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O et al. Association of the RGS2 gene with extrapyramidal symptoms (EPS) induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007; 17: 519\u2013528.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj20086_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/01.hjh.0000226202.80689.8f","volume":"24","author":"A Semplicini","year":"2006","unstructured":"Semplicini A, Lenzini L, Sartori M, Papparella I, Cal\u00f2 LA, Pagnin E et al. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1\/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24: 1115\u20131124.","journal-title":"J Hypertens"},{"key":"BFtpj20086_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1124\/pr.54.3.527","volume":"54","author":"S Hollinger","year":"2002","unstructured":"Hollinger S, Hepler JR . Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54: 527\u2013559.","journal-title":"Pharmacol Rev"},{"key":"BFtpj20086_CR11","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1471-4159.2003.01610.x","volume":"84","author":"JM Taymans","year":"2003","unstructured":"Taymans JM, Leysen JE, Langlois X . Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem 2003; 84: 1118\u20131127.","journal-title":"J Neurochem"},{"key":"BFtpj20086_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.cellsig.2003.11.006","volume":"16","author":"A Ghavami","year":"2004","unstructured":"Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal 2004; 16: 711\u2013721.","journal-title":"Cell Signal"},{"key":"BFtpj20086_CR13","doi-asserted-by":"publisher","first-page":"21248","DOI":"10.1074\/jbc.M312407200","volume":"279","author":"LS Bernstein","year":"2004","unstructured":"Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, Levey AI et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq\/11alpha signaling. J Biol Chem 2004; 279: 21248\u201321256.","journal-title":"J Biol Chem"},{"key":"BFtpj20086_CR14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0022-3565(24)35129-8","volume":"291","author":"MN Potenza","year":"1999","unstructured":"Potenza MN, Gold SJ, Roby-Shemkowitz A, Lerner MR, Nestler EJ . Effects of regulators of G protein-signaling proteins on the functional response of the mu-opioid receptor in a melanophore-based assay. J Pharmacol Exp Ther 1999; 291: 482\u2013491.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj20086_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ng1450","volume":"36","author":"B Yalcin","year":"2004","unstructured":"Yalcin B, Willis-Owen SA, Fullerton J, Meesaq A, Deacon RM, Rawlins JN et al. Genetic dissection of a behavioral quantitative trait locus shows that Rgs2 modulates anxiety in mice. Nat Genet 2004; 36: 1197\u20131202.","journal-title":"Nat Genet"},{"key":"BFtpj20086_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1172\/JCI15598","volume":"111","author":"SP Heximer","year":"2003","unstructured":"Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003; 111: 445\u2013452.","journal-title":"J Clin Invest"},{"key":"BFtpj20086_CR17","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00702-006-0484-8","volume":"113","author":"A Leygraf","year":"2006","unstructured":"Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J et al. Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm 2006; 113: 1921\u20131925.","journal-title":"J Neural Transm"},{"key":"BFtpj20086_CR18","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1126\/science.1069424","volume":"296","author":"SB Gabriel","year":"2002","unstructured":"Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225\u20132229.","journal-title":"Science"},{"key":"BFtpj20086_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00439-006-0180-7","volume":"120","author":"JM Chen","year":"2006","unstructured":"Chen JM, F\u00e9rec C, Cooper DN . A systematic analysis of disease-associated variants in the 3\u2032 regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006; 120: 1\u201321.","journal-title":"Hum Genet"},{"issue":"Suppl","key":"BFtpj20086_CR20","first-page":"25","volume":"65","author":"DE Casey","year":"2004","unstructured":"Casey DE . Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65 (Suppl): 25\u201328.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj20086_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA . Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79\u2013104.","journal-title":"Mol Psychiatry"},{"key":"BFtpj20086_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000098097","volume":"79","author":"G Ho","year":"2007","unstructured":"Ho G, Wang Y, Jones PG, Young KH . Activation of serum response element by D2 dopamine receptor is governed by Gbetagamma-mediated MAPK and Rho pathways and regulated by RGS proteins. Pharmacology 2007; 79: 114\u2013121.","journal-title":"Pharmacology"},{"key":"BFtpj20086_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1460-9568.2006.04970.x","volume":"24","author":"GD Stanwood","year":"2006","unstructured":"Stanwood GD, Parlaman JP, Levitt P . Genetic or pharmacological inactivation of the dopamine D1 receptor differentially alters the expression of regulator of G-protein signalling (RGS) transcripts. Eur J Neurosci 2006; 24: 806\u2013818.","journal-title":"Eur J Neurosci"},{"key":"BFtpj20086_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.neuroscience.2005.04.047","volume":"134","author":"JM Taymans","year":"2005","unstructured":"Taymans JM, Kia HK, Groenewegen HJ, Leysen JE, Langlois X . Bilateral control of brain activity by dopamine D1 receptors: evidence from induction patterns of regulator of G protein signaling 2 and c-fos mRNA in D1-challenged hemiparkinsonian rats. Neuroscience 2005; 134: 643\u2013656.","journal-title":"Neuroscience"},{"key":"BFtpj20086_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1124\/mol.104.005827","volume":"66","author":"SC Tovey","year":"2004","unstructured":"Tovey SC, Willars GB . Single-cell imaging of intracellular Ca2+ and phospholipase C activity reveals that RGS 2, 3, and 4 differentially regulate signaling via the Galphaq\/11-linked muscarinic M3 receptor. Mol Pharmacol 2004; 66: 1453\u20131464.","journal-title":"Mol Pharmacol"},{"key":"BFtpj20086_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3940(01)01923-1","volume":"307","author":"EA Robinet","year":"2001","unstructured":"Robinet EA, Geurts M, Maloteaux JM, Pauwels PJ . Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA. Neurosci Lett 2001; 307: 45\u201348.","journal-title":"Neurosci Lett"},{"key":"BFtpj20086_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/sj.npp.1301002","volume":"31","author":"SH Fatemi","year":"2006","unstructured":"Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 2006; 31: 1888\u20131899.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj20086_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S1461145705005110","volume":"8","author":"R Smith","year":"2005","unstructured":"Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A . Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 2005; 8: 183\u2013194.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj20086_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"S Kay","year":"1987","unstructured":"Kay S, Fiszbein A, Opler LA . The Positive And Negative Syndrome scale for schizophrenia. Schizophr Bull 1987; 13: 261\u2013276.","journal-title":"Schizophr Bull"},{"key":"BFtpj20086_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"G Simpson","year":"1970","unstructured":"Simpson G, Angus MP . Scale for assessment extrapyramidal side effects. Acta Psychiatr Scand 1970; 212: 11\u201319.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtpj20086_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR . A rating scale for drug induced akathisia. Br J Psychiatry 1989; 154: 672\u2013676.","journal-title":"Br J Psychiatry"},{"key":"BFtpj20086_CR32","first-page":"365","volume-title":"Bioinformatics Methods and Protocols: Methods in Molecular Biology","author":"S Rozen","year":"2000","unstructured":"Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers.In: Krawetz S, Misener S (eds). Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000. Humana Press: Totowa, NJ.pp. 365\u2013386."},{"key":"BFtpj20086_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/319501","volume":"68","author":"M Stephens","year":"2001","unstructured":"Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978\u2013989.","journal-title":"Am J Hum Genet"},{"key":"BFtpj20086_CR34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1086\/379378","volume":"73","author":"M Stephens","year":"2003","unstructured":"Stephens M, Donnelly P . A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162\u20131169.","journal-title":"Am J Hum Genet"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj20086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj20086","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj20086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T04:19:09Z","timestamp":1738124349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj20086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,18]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["BFtpj20086"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2008.6","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,18]]},"assertion":[{"value":"13 December 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}